Compare Deckers Outdoor Corp (DECK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Deckers Outdoor Corp trades at $82.62 (market cap $10.95B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.7× Deckers Outdoor Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DECK | VRTX | |
|---|---|---|
Market Cap | $10.95B | $128.16B |
Volume | 3,090,240 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $557.96 |
52-Week Low | $77.51 | $407.37 |
Typical Hold Time | 71 Days | 120 Days |
Enterprise Value | $9.82B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $80.38, down 1.57% today, with strong fundamentals including 19.37% net margin and consistent earnings beats. The stock shows neutral technical signals with support at $78-79 and resistance at $81-82. Revenue growth has accelerated from $3.2B in 2022 to $5.0B in 2025, while profitability metrics remain robust with 42.56% ROE.
DECK presents a compelling value opportunity with attractive valuation multiples (P/E 11.43, EV/EBITDA 7.06) and 46% upside to consensus price target of $117.13. Risks include potential margin pressure from competitive footwear market and projected negative cash flow in 2026. Analyst sentiment leans bullish with 45% buy ratings versus 11% sell recommendations.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
